News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Ravi Salgia: Wonderful turnout for the 14th Medical Oncology Advances Symposium
ilcn.org
Nov 17, 2024, 16:35

Ravi Salgia: Wonderful turnout for the 14th Medical Oncology Advances Symposium

Ravi Salgia, Professor and Chair in the Department of Medical Oncology at City of Hope, shared a post on X:

“Wonderful turnout for the 14th Medical Oncology Advances Symposium! Great presenters and leadership from ⁦Linda Bosserman, Nishan Tchekmedyian in organizing/moderating!”

Ravi Salgia

14th Medical Oncology Advances Symposium cancer City of Hope Linda Bosserman Nishan Tchekmedyian OncoDaily Oncology Ravi Salgia
Special Coverage
Insight
Mar 27, 2025, 16:40
Raffaele Colombo: First ever dual payload ADC in the clinic
Blog
Mar 27, 2025, 15:53
Highlights from ELCC Day 1
Blog
Mar 27, 2025, 15:44
Fabio Ynoe de Moraes: The power of resilience in sports and research
Blog
Mar 27, 2025, 15:42
Sabine D. Brookman-May: Great EAU25 with Excellent Abstract and Topic Selection
Dialogues
Mar 27, 2025, 15:24
Episode 3 with Jasmin Hundal – Cancer Through My Eyes
Blog
Mar 27, 2025, 15:23
CancerWorld: Why Immune Checkpoint Inhibitors do not work?
Blog
Mar 27, 2025, 15:09
Shushan Hovsepyan: Michael Wagner on Current and Promising Angiosarcoma Treatments
Blog
Mar 27, 2025, 14:59
Celebrating World Psycho-Oncology Day - IPOS
Blog
Mar 27, 2025, 14:53
Peter Pisters: Jeffrey E. Lee has been appointed as MD Anderson Cancer Center's Chief Medical Executive
Blog
Mar 27, 2025, 14:45
Subcutaneous pembrolizumab demonstrated noninferiority compared with IV pembrolizumab in the phase III MK-3475A-D77 trial - European Society for Medical Oncology
Blog
Mar 27, 2025, 14:37
Kimryn Rathmell presented the Paul Calabresi Memorial Lecture - Yale Cancer Center
Blog
Mar 27, 2025, 14:29
Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC - ESMO